AI Summary Victoza (liraglutide) is a once-daily injection approved to help manage type 2 diabetes and to reduce the risk of major cardiovascular events in certain adults with established cardiovascular disease.
Medically Reviewed.
Victoza (liraglutide) is a prescription GLP-1 receptor agonist approved to manage type 2 diabetes and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It mimics a natural hormone that regulates blood sugar and appetite. Because obesity, insulin resistance, and type 2 diabetes drive MASLD and MASH, some healthcare providers explore or prescribe Victoza for eligible patients to address these metabolic risk factors. By supporting weight management and better blood sugar control, it may help improve the metabolic health factors linked to liver disease, though it is not a direct liver treatment. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Victoza's role in MASLD and MASH management — how it works, who may be eligible, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether Victoza fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT VICTOZA TREATMENT
Victoza is a prescription medicine that contains liraglutide, a type of medication known as a GLP-1 receptor agonist. It mimics a natural hormone that helps regulate blood sugar and appetite, slowing stomach emptying and helping your body respond better to its own insulin.
Victoza is approved to help manage type 2 diabetes and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Because obesity, insulin resistance, and elevated blood sugar are closely linked to MASLD and MASH, some healthcare providers prescribe Victoza to address these underlying metabolic risk factors, even though it is not a direct liver treatment.
It is typically used as part of a broader, personalised treatment plan that may include dietary changes, physical activity, and regular monitoring by your healthcare provider, such as Liver Function Tests (LFTs) or imaging.
WHO VICTOZA MAY BE SUITABLE FOR
Eligibility for Victoza depends on your diagnosis and individual health needs. Victoza is approved to help manage type 2 diabetes and reduce cardiovascular risk in certain adults, and it may be considered for people who meet those criteria and who also have MASLD or MASH linked to metabolic risk factors such as obesity, insulin resistance, or elevated blood sugar.
Your medical history, current health status, liver condition, and any other medications you take all factor into whether Victoza is an appropriate option for you.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should take Victoza. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your liver condition, metabolic health, and treatment goals. Your doctor will weigh the potential benefits against any risks before determining whether Victoza fits safely into your broader care plan.
ELIGIBILITY OVERVIEW
Victoza may be considered for adults with the following conditions, risk factors, or treatment goals:
Before recommending Victoza, healthcare providers evaluate several factors to determine whether it is an appropriate option, including:
HOW VICTOZA CAN HELP YOUR LIVER
Victoza activates GLP-1 receptors, which prompts the pancreas to release more insulin when blood sugar rises and reduces glucagon, a hormone that signals the liver to produce glucose. It also slows how quickly food leaves the stomach, lowering after-meal blood sugar spikes and reducing appetite.
These actions target the metabolic drivers behind MASLD and MASH: insulin resistance, chronically elevated blood sugar, and excess body weight. As insulin resistance improves and the liver produces less glucose, fat tends to build up less in liver cells, and the inflammation that drives disease progression may ease.
For patients with MASLD or MASH, these metabolic changes can support treatment goals such as better blood sugar control, gradual weight loss, and a lower risk of disease progression. Victoza is not used on its own — providers pair it with dietary changes, physical activity, and regular monitoring, such as Liver Function Tests (LFTs), to support these outcomes.
LIVER BENEFITS
Insulin resistance and excess weight are major contributors to fat buildup in liver cells. By supporting weight management and improving insulin sensitivity, Victoza addresses these underlying drivers and may help reduce the amount of fat stored in the liver.
Insulin resistance is a central metabolic pathway in MASLD and MASH. Victoza helps the body use insulin more effectively and lowers the amount of glucose released by the liver, supporting healthier blood sugar regulation.
Weight reduction is one of the most effective ways to improve fatty liver disease. Victoza reduces appetite and slows digestion, which can support gradual weight loss when combined with dietary and lifestyle changes.
MASLD can progress to MASH, liver fibrosis, or cirrhosis over time. Improving the metabolic factors above — weight, insulin resistance, and blood sugar control — may help lower risk factors linked to disease progression, although individual outcomes vary.
Victoza supports metabolic health by improving blood sugar control and aiding weight management, which may help people with MASLD or MASH. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Victoza comes in a prefilled injection pen used to inject the medication under the skin. Check the solution before each dose to ensure it is clear and colorless. If it looks cloudy, discolored, or contains particles, do not use it — contact your pharmacist or healthcare provider instead.
Victoza is delivered as a once-daily injection under the skin (subcutaneously), into the abdomen, thigh, or upper arm. Rotate injection sites regularly to help avoid skin irritation.
The usual starting dose is 0.6 mg once daily for one week, allowing the body to adjust to the medication. The dose is then increased to 1.2 mg once daily. If additional blood sugar control is needed, the dose may be increased further to 1.8 mg once daily. Your healthcare provider determines the right dose and any adjustments based on how you respond.
Clean the injection site with an alcohol swab and follow the instructions provided with the injection pen. Always use Victoza exactly as your healthcare provider directs.
Victoza is generally used as a long-term therapy to help maintain blood sugar control and reduce the risk of diabetes-related complications. Continue treatment as prescribed, and do not discontinue the medication without first talking to your healthcare provider.
Store unused pens in the refrigerator, protected from excessive heat and light.
Your healthcare provider will regularly check your blood glucose and HbA1c levels to assess how well the medication is working and adjust treatment if needed. For people using Victoza to support MASLD or MASH management, providers may also monitor liver health measures, such as Liver Function Tests (LFTs), alongside routine follow-up. Report any side effects or unusual symptoms to your healthcare provider.
BENEFITS AND SAFETY
Victoza (liraglutide) may support people with MASLD and MASH by targeting the metabolic risk factors — excess weight, insulin resistance, and elevated blood sugar — that drive fat buildup and inflammation in the liver. By helping the body respond better to insulin and supporting gradual weight loss, it may contribute to reduced liver fat and a lower risk of disease progression over time. The extent of these benefits varies from person to person, depending on their liver condition, overall metabolic health, treatment plan, and how their body responds to therapy. Victoza is not a stand-alone liver treatment — it works best as part of a broader, personalised care plan that combines the medication with lifestyle changes, such as a liver-healthy diet and regular physical activity, along with ongoing monitoring like Liver Function Tests (LFTs) or imaging.
As with any medication, Victoza may cause side effects, ranging from mild digestive symptoms to less common reactions. Your healthcare provider will assess whether Victoza is a suitable option for you and will monitor your treatment response throughout therapy, adjusting the dose or overall care plan as needed to balance potential benefits against any risks.
BENEFITS
Victoza helps reduce HbA1c and improve overall glycemic control by increasing insulin release when blood sugar is high and reducing glucagon, a hormone that signals the liver to produce glucose.
In certain adults with type 2 diabetes and established cardiovascular disease, Victoza may reduce the risk of major cardiovascular events such as heart attack and stroke.
Victoza may support gradual weight loss by reducing appetite and slowing digestion, when combined with diet and exercise. Because excess weight drives fat buildup in the liver, this benefit may help reduce liver fat in people with MASLD or MASH.
Victoza is a once-daily injection, offering a non-insulin treatment option for people who want consistent blood sugar control without frequent daily insulin dosing.
These effects are often more noticeable when starting treatment or adjusting the dose and may improve over time. Your healthcare provider will discuss the potential benefits and risks before treatment and provide ongoing support to ensure safe use.
SUPPORTING YOUR RESULTS
Lifestyle changes are often an important part of a comprehensive treatment plan alongside medication such as Victoza. Depending on your condition and overall care plan, your healthcare provider may recommend adjustments in areas such as nutrition, physical activity, weight management, sleep, or other healthy habits.
These changes may help improve how your body responds to treatment and support better outcomes and overall health over time. Your healthcare provider can help determine which changes are most relevant to your situation.
Areas that may support treatment, depending on your condition and care plan:
COMMON QUESTIONS
No, Victoza is not a direct liver treatment. Its approved uses are to help manage type 2 diabetes and to reduce the risk of major cardiovascular events in certain adults with type 2 diabetes and established cardiovascular disease. Obesity, insulin resistance, and elevated blood sugar drive MASLD and MASH, so some healthcare providers prescribe Victoza to address those metabolic risk factors as part of a broader liver care plan. Whether it fits your care plan is a decision for you and your healthcare provider.
Liraglutide is a GLP-1 receptor agonist, a medicine that mimics a natural hormone in your body. That hormone helps regulate blood sugar and appetite. Liraglutide increases insulin release when blood sugar is high, lowers the amount of glucose your liver releases, and slows how fast food leaves your stomach. Unlike insulin, Victoza does not replace insulin. It helps your body manage blood glucose more effectively.
Victoza is a once-daily injection under the skin, using a prefilled pen. You can inject into the abdomen, thigh, or upper arm, and you should rotate sites regularly. The usual starting dose is 0.6 mg once daily for one week, then 1.2 mg once daily. If more blood sugar control is needed, the dose may go up to 1.8 mg once daily. Your healthcare provider sets and adjusts your dose, so always use Victoza exactly as directed. This differs from once-weekly options such as Ozempic or Mounjaro.
The most common side effects are digestive: nausea, vomiting, diarrhea, and constipation. Some people also notice decreased appetite or abdominal discomfort and bloating. Injection site reactions are uncommon. These effects are often more noticeable when you start treatment or change your dose, and they may improve over time. Report any side effects or unusual symptoms to your healthcare provider, who can weigh benefits and risks and adjust your plan.
No. Victoza works best alongside a healthy, balanced diet, regular physical activity, weight management, and other habits your healthcare provider recommends. These habits can improve blood sugar control and support overall metabolic and cardiovascular health. For people with MASLD or MASH, Victoza is not a stand-alone liver treatment, so medication does not replace these changes.
Both medicines contain liraglutide, but they are used for different purposes. Victoza is used to manage type 2 diabetes and reduce cardiovascular risk in certain adults. Saxenda is used at a higher dose and is indicated for chronic weight management rather than type 2 diabetes treatment. Never switch between them or change your dose on your own. Your healthcare provider can explain which one fits your health needs.
Victoza is generally used as a long-term therapy to help maintain blood sugar control and reduce the risk of diabetes-related complications. Continue it as prescribed, and do not stop without talking to your healthcare provider first. Your provider will regularly check your blood glucose and HbA1c levels. If you also have MASLD or MASH, they may monitor liver health with measures such as Liver Function Tests (LFTs) during routine follow-up.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
